<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648634</url>
  </required_header>
  <id_info>
    <org_study_id>P090202</org_study_id>
    <nct_id>NCT01648634</nct_id>
  </id_info>
  <brief_title>Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy</brief_title>
  <acronym>NEBIDYS</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Examine the Effect of Nebivolol, a Beta-Blockade Drug, for the Prevention of Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Française contre les Myopathies (AFM), Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to determine whether nebivolol, a beta-blockade drug, can prevent the
      development of heart disease in patients with Duchenne muscular dystrophy aged 10 to 15
      year-old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 1.25 mg-test dose will be administrated to assess the treatment tolerance before
      randomization. A forced titration of nebivolol and placebo will be performed with 2 weeks
      periods. Full dose of nebivolol and placebo is 5mg/day (7.5mg/day for patients whose weight
      is&gt;60kg).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 13, 2012</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular systolic dysfunction</measure>
    <time_frame>at 5 years</time_frame>
    <description>Development of left ventricular systolic dysfunction with an ejection fraction &lt; 45%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Right ventricular ejection fraction</measure>
    <time_frame>at 5 years</time_frame>
    <description>Right ventricular ejection fraction assessed by radionuclide angiography or echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-ProBNP</measure>
    <time_frame>at 1, 2, 3, 4, and 5 years</time_frame>
    <description>NT-ProBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular dysfunction</measure>
    <time_frame>at 10 years</time_frame>
    <description>Development of left ventricular dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>at 10 years</time_frame>
    <description>hospitalizations for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>at 10 years ((5-years open label extension)</time_frame>
    <description>Cardiovascular mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Cardiomyopathy</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is&gt;60kg)</description>
    <arm_group_label>Nebivolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is&gt;60kg)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Duchenne muscular dystrophy genetically proven

          -  Age between 10 and 15 years

          -  Left ventricular ejection fraction assessed by radionuclide angiography or
             echocardiography ≥50% and measured within 3 months

          -  Systolic blood pressure ≥80 mmHg

          -  Diastolic blood pressure ≥70 mmHg

        Exclusion Criteria:

          -  Heart rate &lt;50 bpm

          -  2nd or 3rd degree atrioventricular blocks, sinus node dysfunction

          -  Asthma or bronchospasm

          -  Severe peripheral circulatory disease

          -  Hypersensitivity to nebivolol or excipients

          -  Metabolic acidosis

          -  Blood urea &gt;7 mmol/l

          -  Liver transaminases enzymes &gt;6 fold the upper limit of normal

          -  Formal indication for beta-blockade treatment

          -  Cardiac treatments except angiotensin-converting enzyme inhibitors

          -  Participation to another clinical trial within 3 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri-Marc BECANE, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Armand Trousseau Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Armand Trousseau Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nebivolol</keyword>
  <keyword>beta-blockade treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

